Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-Mutant Pancreatic Cancer
Craig M. Goodwin, Andrew M. Waters, Jennifer E. Klomp, et al.
Cancer Research (2022) Vol. 83, Iss. 1, pp. 141-157
Open Access | Times Cited: 84

Showing 1-25 of 84 citing articles:

Targeting KRAS in cancer
Anupriya Singhal, Bob T. Li, Eileen M. O’Reilly
Nature Medicine (2024) Vol. 30, Iss. 4, pp. 969-983
Closed Access | Times Cited: 73
Treatment Strategies for KRAS-Mutated Non-Small-Cell Lung Cancer
E O'Sullivan, Anna Keogh, Brian E. Henderson, et al.
Cancers (2023) Vol. 15, Iss. 6, pp. 1635-1635
Open Access | Times Cited: 47
Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma
Abdelrahman Yousef, Mahmoud Yousef, Saikat Chowdhury, et al.
npj Precision Oncology (2024) Vol. 8, Iss. 1
Open Access | Times Cited: 40
Combinatorial strategies to target RAS-driven cancers
Naiara Perurena, Lisa Situ, Karen Cichowski
Nature reviews. Cancer (2024) Vol. 24, Iss. 5, pp. 316-337
Closed Access | Times Cited: 28
Determining the ERK-regulated phosphoproteome driving KRAS-mutant cancer
Jennifer E. Klomp, J. Nathaniel Diehl, Jeffrey A. Klomp, et al.
Science (2024) Vol. 384, Iss. 6700
Open Access | Times Cited: 21
Targeting KRAS: from metabolic regulation to cancer treatment
Yanyan Shi, Huiling Zheng, Tianzhen Wang, et al.
Molecular Cancer (2025) Vol. 24, Iss. 1
Open Access | Times Cited: 4
A Small Molecule with Big Impact: MRTX1133 Targets the KRASG12D Mutation in Pancreatic Cancer
Daoyan Wei, Liang Wang, Xiangsheng Zuo, et al.
Clinical Cancer Research (2023) Vol. 30, Iss. 4, pp. 655-662
Open Access | Times Cited: 39
Impact of context-dependent autophagy states on tumor progression
Mohamad Assi, Alec C. Kimmelman
Nature Cancer (2023) Vol. 4, Iss. 5, pp. 596-607
Open Access | Times Cited: 29
Cuproptosis and cuproptosis-related genes: Emerging potential therapeutic targets in breast cancer
Xiangdong Liu, Bo Luo, Xinhong Wu, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2023) Vol. 1878, Iss. 6, pp. 189013-189013
Closed Access | Times Cited: 28
Targeting KRAS mutations in pancreatic cancer: opportunities for future strategies
Anna Linehan, Mary O’Reilly, Ray McDermott, et al.
Frontiers in Medicine (2024) Vol. 11
Open Access | Times Cited: 14
KRAS inhibitors: resistance drivers and combinatorial strategies
Tamara Isermann, Christine Sers, Channing J. Der, et al.
Trends in cancer (2024)
Open Access | Times Cited: 11
Integrating CRISPR Technology with Key Genetic Markers in Pancreatic Cancer: A New Frontier in Targeted Therapies
Dimitrios Stefanoudakis
SynBio (2025) Vol. 3, Iss. 1, pp. 1-1
Open Access | Times Cited: 1
A stumbling block in pancreatic cancer treatment: drug resistance signaling networks
Jinming Liu, Biao Zhang, Bingqian Huang, et al.
Frontiers in Cell and Developmental Biology (2025) Vol. 12
Open Access | Times Cited: 1
Microfluidic fabrication of lipid nanoparticles for co-delivery of siRNA and hydroxychloroquine: An engineered theranostic platform for enhanced breast cancer treatment
Lu Huang, Wenli Guo, Ting Zhao, et al.
Chemical Engineering Journal (2025), pp. 160172-160172
Open Access | Times Cited: 1
Targeting KRAS in Pancreatic Ductal Adenocarcinoma: The Long Road to Cure
Victor Hugo Fonseca de Jesus, Maria Cecília Mathias-Machado, João Paulo Fogacci de Farias, et al.
Cancers (2023) Vol. 15, Iss. 20, pp. 5015-5015
Open Access | Times Cited: 17
Six‐Membered Aromatic Nitrogen Heterocyclic Anti‐Tumor Agents: Synthesis and Applications
Jiatong Li, Ao Gu, Xiao‐Mei Nong, et al.
The Chemical Record (2023) Vol. 23, Iss. 12
Closed Access | Times Cited: 17
Genetic Signature of Human Pancreatic Cancer and Personalized Targeting
Stephan J. Reshkin, Rosa Angela Cardone, Tomas Koltai
Cells (2024) Vol. 13, Iss. 7, pp. 602-602
Open Access | Times Cited: 8
Biomimetic Targeted Co‐Delivery System Engineered from Genomic Insights for Precision Treatment of Osteosarcoma
Tianqi Luo, Zhijin Fan, Anyu Zeng, et al.
Advanced Science (2024) Vol. 12, Iss. 2
Open Access | Times Cited: 8
Targeting autophagy drug discovery: Targets, indications and development trends
Mengjia Jiang, Wayne Wu, Zijie Xiong, et al.
European Journal of Medicinal Chemistry (2024) Vol. 267, pp. 116117-116117
Closed Access | Times Cited: 7
Targeting RAF dimers in RAS mutant tumors: From biology to clinic
Huanhuan Yin, Qiulin Tang, Hongwei Xia, et al.
Acta Pharmaceutica Sinica B (2024) Vol. 14, Iss. 5, pp. 1895-1923
Open Access | Times Cited: 7
Conformation selection by ATP-competitive inhibitors and allosteric communication in ERK2
Jake W. Anderson, David Vaisar, David N. M. Jones, et al.
eLife (2024) Vol. 12
Open Access | Times Cited: 6
Cancer takes many paths through G1/S
Erik S. Knudsen, Agnieszka K. Witkiewicz, Seth M. Rubin
Trends in Cell Biology (2023) Vol. 34, Iss. 8, pp. 636-645
Closed Access | Times Cited: 15
Enhanced Apoptosis and Loss of Cell Viability in Melanoma Cells by Combined Inhibition of ERK and Mcl-1 Is Related to Loss of Mitochondrial Membrane Potential, Caspase Activation and Upregulation of Proapoptotic Bcl-2 Proteins
Zhe Peng, Bernhard Gillissen, Antje Richter, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 5, pp. 4961-4961
Open Access | Times Cited: 12
The BRD4 inhibitor JQ1 augments the antitumor efficacy of abemaciclib in preclinical models of gastric carcinoma
Mei Feng, Hao Xu, Wenyuan Zhou, et al.
Journal of Experimental & Clinical Cancer Research (2023) Vol. 42, Iss. 1
Open Access | Times Cited: 11
Villosol reverses 5-FU resistance in colorectal cancer by inhibiting the CDKN2A gene regulated TP53-PI3K/Akt signaling axis
Han Chen, Jiao Deng, Tiewei Hou, et al.
Journal of Ethnopharmacology (2024) Vol. 325, pp. 117907-117907
Closed Access | Times Cited: 4
Page 1 - Next Page

Scroll to top